[Inclusion body myositis].
Inclusion body myositis has been recently recognized as a clinical entity although its exact definition remains uncertain. Initially considered to be an inflammatory dermatomyositis, inclusion body myositis can actually take on three specific forms: disseminated muscle atrophy and weakness, pseudopolymyositis, or pseudo-degenerative disease. Inclusion body myositis is different from non-inflammatory neuromuscular diseases with vacuoles. Abnormal deposits are seen within the muscle fiber may contain amyloid substance, beta-amyloid precursor, ubiquitin, antichymotrypsin, protein tau, apolipoprotein E and even prions. The signification of these deposits is unknown. Deletions in mitochondrial DNA have been demonstrated but do not appear to play a causal role. More and more hereditary forms are being recognized and certain may be related to an abnormality in chromosome 9.
Serratrice
G
G
Service de Neurologie et des Maladies neuromusculaires, CHU La Timone, Marseille.
D016229:Amyloid beta-Peptides / Q000096:biosynthesis*; D001327:Autoimmune Diseases / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D018979:Myositis, Inclusion Body / Q000150:complications* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D011328:Prions / Q000096:biosynthesis; D014452:Ubiquitins / Q000096:biosynthesis*; D000514:alpha 1-Antichymotrypsin / Q000096:biosynthesis; D016875:tau Proteins / Q000096:biosynthesis
D016229:Amyloid beta-Peptides; D011328:Prions; D014452:Ubiquitins; D000514:alpha 1-Antichymotrypsin; D016875:tau Proteins
La myosite à inclusions.